-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer, a large multinational pharmaceutical company, is expected to reduce its sales force in the United States after the epidemic ends, according to Reuters
.
This news quickly attracted the attention of the industry
.
According to the report, this personnel change is because Pfizer is developing into a biopharmaceutical company that focuses more on innovation, and will change the way it interacts with medical business personnel in the era of gradual digitalization.
After the change, it will ensure that it has the right resources to Meet the changing needs of the market
.
However, in this statement, Pfizer did not disclose the specific number of personnel reductions
.
From the above statement, two key points can be grasped, one is innovation, and the other is digitalization.
These two points are also the major directions of the development of the pharmaceutical industry in recent years
.
In terms of innovation, in the context of fierce competition in the global pharmaceutical market, it has become a trend for pharmaceutical companies to focus on innovation.
Only through innovation can they gain more competitiveness; and in terms of digitalization, since 2020, the digitalization model has accelerated into people's Life and production, especially for enterprises, the advantages of digital efficient production, unmanned or less human contact are prominent, making up for the traditional production, management, service and other methods
.
It is reported that Pfizer has previously said that in the future doctors and other health care professionals expect about half of their interactions with pharmaceutical companies to be remote
.
In fact, in recent years, under the background of accelerating changes in the pharmaceutical landscape, layoffs, personnel changes, and business adjustments seem to have become normal actions for both multinational and local pharmaceutical companies
.
For example, on November 15, 2021, AstraZeneca China announced the adjustment of some business structures, splitting and county businesses, and integrating the county oncology business into the oncology business unit, and the non-oncology business being independent, becoming the county chronic disease business unit; At the same time, it also announced the merger of the Cardiovascular and Metabolism Business Unit and the Renal Business Unit to form the Cardiovascular, Renal and Metabolism Business Unit
.
In this round of adjustment, there are also personnel changes.
AstraZeneca appointed Liu Qian, the vice president of China, as the head of the omni-channel business unit, and Zhu Lili, the vice president of AstraZeneca China.
.
On January 1, 2022, AstraZeneca China Omni-Channel Business Department was unveiled.
It is reported that the department will be responsible for AstraZeneca China and County Chronic Disease Business Department, Retail Business Department, Community Business Department, Flying Eagle Business Department and Dongwu County Area market work
.
Looking back at the past few years, China's centralized procurement policy has had a significant impact on multinational pharmaceutical companies, and news of layoffs has continued
.
For example, the Japanese pharmaceutical company Daiichi Sankyo plans to merge the cardiovascular, anti-infective and respiratory analgesia lines, and lay off the personnel of the relevant teams.
Sodium) and the anti-infective line of Colabitux (levofloxacin) were included, but were not successfully selected; Eli Lilly announced the adjustment of the sales and regional marketing team of Ou Tangjing (Embagliflozin), and the cancellation of Cymbalta (Durohydrochloride) The sales team of several products such as Xetine) and Cialis (tadalafil), none of the above three products were selected in the centralized procurement; after the sixth round of insulin special centralized procurement, they participated in the centralized procurement and all products were selected.
Novo Nordisk quickly spread the news that it would lay off 15%-20% of its employees nationwide
.
Not only multinational pharmaceutical companies, but also local pharmaceutical companies have reported layoffs as frequently
.
For example, Hengrui Medicine mentioned in its 2021 semi-annual report that it will “strengthen the troops and simplify the administration”
.
Hengrui Medicine, since 2018, it has entered a total of 28 varieties of generic drugs that have been purchased by the state, and 18 varieties have been selected.
The average price of the selected drugs has dropped by 72.
6%, which has caused great pressure on its performance
.
At the same time, the domestic innovative biopharmaceutical industry has serious homogenization competition, and biopharmaceutical innovation is facing severe challenges
.
.
This news quickly attracted the attention of the industry
.
According to the report, this personnel change is because Pfizer is developing into a biopharmaceutical company that focuses more on innovation, and will change the way it interacts with medical business personnel in the era of gradual digitalization.
After the change, it will ensure that it has the right resources to Meet the changing needs of the market
.
However, in this statement, Pfizer did not disclose the specific number of personnel reductions
.
From the above statement, two key points can be grasped, one is innovation, and the other is digitalization.
These two points are also the major directions of the development of the pharmaceutical industry in recent years
.
In terms of innovation, in the context of fierce competition in the global pharmaceutical market, it has become a trend for pharmaceutical companies to focus on innovation.
Only through innovation can they gain more competitiveness; and in terms of digitalization, since 2020, the digitalization model has accelerated into people's Life and production, especially for enterprises, the advantages of digital efficient production, unmanned or less human contact are prominent, making up for the traditional production, management, service and other methods
.
It is reported that Pfizer has previously said that in the future doctors and other health care professionals expect about half of their interactions with pharmaceutical companies to be remote
.
In fact, in recent years, under the background of accelerating changes in the pharmaceutical landscape, layoffs, personnel changes, and business adjustments seem to have become normal actions for both multinational and local pharmaceutical companies
.
For example, on November 15, 2021, AstraZeneca China announced the adjustment of some business structures, splitting and county businesses, and integrating the county oncology business into the oncology business unit, and the non-oncology business being independent, becoming the county chronic disease business unit; At the same time, it also announced the merger of the Cardiovascular and Metabolism Business Unit and the Renal Business Unit to form the Cardiovascular, Renal and Metabolism Business Unit
.
In this round of adjustment, there are also personnel changes.
AstraZeneca appointed Liu Qian, the vice president of China, as the head of the omni-channel business unit, and Zhu Lili, the vice president of AstraZeneca China.
.
On January 1, 2022, AstraZeneca China Omni-Channel Business Department was unveiled.
It is reported that the department will be responsible for AstraZeneca China and County Chronic Disease Business Department, Retail Business Department, Community Business Department, Flying Eagle Business Department and Dongwu County Area market work
.
Looking back at the past few years, China's centralized procurement policy has had a significant impact on multinational pharmaceutical companies, and news of layoffs has continued
.
For example, the Japanese pharmaceutical company Daiichi Sankyo plans to merge the cardiovascular, anti-infective and respiratory analgesia lines, and lay off the personnel of the relevant teams.
Sodium) and the anti-infective line of Colabitux (levofloxacin) were included, but were not successfully selected; Eli Lilly announced the adjustment of the sales and regional marketing team of Ou Tangjing (Embagliflozin), and the cancellation of Cymbalta (Durohydrochloride) The sales team of several products such as Xetine) and Cialis (tadalafil), none of the above three products were selected in the centralized procurement; after the sixth round of insulin special centralized procurement, they participated in the centralized procurement and all products were selected.
Novo Nordisk quickly spread the news that it would lay off 15%-20% of its employees nationwide
.
Not only multinational pharmaceutical companies, but also local pharmaceutical companies have reported layoffs as frequently
.
For example, Hengrui Medicine mentioned in its 2021 semi-annual report that it will “strengthen the troops and simplify the administration”
.
Hengrui Medicine, since 2018, it has entered a total of 28 varieties of generic drugs that have been purchased by the state, and 18 varieties have been selected.
The average price of the selected drugs has dropped by 72.
6%, which has caused great pressure on its performance
.
At the same time, the domestic innovative biopharmaceutical industry has serious homogenization competition, and biopharmaceutical innovation is facing severe challenges
.
